Harga Saham & Berita untuk Ligand Pharmaceuticals Inc (LGDN)

Simbol Simbol	Harga	Perubahan	Persentase Perubahan	Tren	Penutupan Sebelumnya	Buka	Tinggi	Rendah	Volume	Kapitalisasi Pasar
SIXB Materials SIXB Materials	SIXB +0,25%	1.104,10	+2,73	+0,25%	—	1.101,37	1.103,63	1.105,31	1.091,41	—	—
SIXC Communications SIXC Communications	SIXC -1,50%	604,16	-9,19	-1,50%	—	613,35	613,35	613,35	601,49	—	—
SIXE Energy SIXE Energy	SIXE -0,09%	1.197,81	-1,02	-0,09%	—	1.198,83	1.199,68	1.199,75	1.182,41	—	—
SIXI Industrials SIXI Industrials	SIXI -0,88%	1.740,41	-15,54	-0,88%	—	1.755,95	1.754,06	1.756,03	1.734,69	—	—
SIXM Financials SIXM Financials	SIXM -0,64%	634,44	-4,07	-0,64%	—	638,51	637,41	637,41	633,05	—	—
SIXR Staples SIXR Staples	SIXR -0,31%	840,90	-2,62	-0,31%	—	843,52	843,35	846,40	837,93	—	—
SIXRE Real estate SIXRE Real estate	SIXRE -0,38%	215,13	-0,82	-0,38%	—	215,95	215,95	216,84	215,06	—	—
SIXT Technology SIXT Technology	SIXT +2,86%	3.228,71	+89,80	+2,86%	—	3.138,91	3.189,30	3.230,85	3.174,76	—	—
SIXU Utilities SIXU Utilities	SIXU +0,16%	935,87	+1,50	+0,16%	—	934,37	934,72	938,26	927,50	—	—
SIXV Health care SIXV Health care	SIXV -1,37%	1.457,12	-20,31	-1,37%	—	1.477,43	1.474,12	1.474,12	1.451,80	—	—
SIXY Discretionary SIXY Discretionary	SIXY +0,83%	2.399,84	+19,65	+0,83%	—	2.380,19	2.389,34	2.403,04	2.380,47	—	—

LGDN:FRA

Ligand Pharmaceuticals Inc

€190,00

0,00%

(0,00) 1 HR

24 Apr, 22.00.00 GMT+2 · EUR

Semua simbol

1 HR

5 HR

1BLN

6BLN

YTD

1THN

5THN

MAKS

	Simbol	Harga	Perubahan	Persentase Perubahan

Membuat insight teratas untuk LGDN...

Buka

€192,00

Tinggi

€192,00

Rendah

€190,00

Kapitalisasi pasar

4,63 M

Volume rata-rata

3,00

Volume

0,00

Harga tinggi dalam 52 minggu terakhir

€195,00

Harga rendah dalam 52 minggu terakhir

€87,00

Jumlah karyawan

Artikel berita

Dari berbagai sumber di seluruh web

MarketBeat

1 jam yang lalu

Impax Asset Management Group plc Sells 35,000 Shares of Ligand Pharmaceuticals Incorporated $LGND

Profil

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia

Tentang Ligand Pharmaceuticals Inc

CEO-

Karyawan47

DidirikanSep 1987

Kantor PusatJupiter, Florida, Amerika Serikat

Sektor-

Situsligand.com

Semua nilai dalam USD	Mar 2025	Jun 2025	Sep 2025	Des 2025
Pendapatan	45,33 jt	47,63 jt	115,46 jt	59,67 jt
Harga pokok penjualan	54,93 jt	9,47 jt	24,82 jt	6,50 jt
Biaya pendapatan	54,93 jt	9,47 jt	24,82 jt	6,50 jt
Biaya riset dan pengembangan	-	-	-	-
Total biaya riset dan pengembangan	-	-	-	-
Biaya penjualan, umum, dan administrasi	18,80 jt	20,18 jt	28,45 jt	25,03 jt
Biaya operasional	27,06 jt	28,43 jt	36,54 jt	33,12 jt
Total biaya operasional	81,99 jt	37,91 jt	61,36 jt	39,63 jt
Penghasilan operasional	-36,66 jt	9,72 jt	54,10 jt	20,04 jt
Penghasilan non-operasional lainnya	-2,06 jt	96,00 rb	390,00 rb	1,48 jt
EBT termasuk item luar biasa	-50,18 jt	11,22 jt	141,14 jt	56,78 jt
EBT tidak termasuk item luar biasa	-37,81 jt	10,28 jt	57,45 jt	116,80 jt
Beban pajak penghasilan	-7,73 jt	6,38 jt	23,86 jt	12,00 jt
Tarif pajak efektif	15,40%	56,81%	16,91%	21,13%
Biaya operasional lainnya	-	-	-	-
Penghasilan bersih	-42,45 jt	4,85 jt	117,27 jt	44,78 jt
Margin laba bersih	-93,64%	10,18%	101,57%	75,06%
Penghasilan per saham	1,33	1,60	3,09	2,02
Penghasilan bunga dan investasi	1,77 jt	1,62 jt	3,87 jt	6,39 jt
Beban bunga	-867,00 rb	-1,15 jt	-910,00 rb	-1,78 jt
Beban bunga bersih	904,00 rb	468,00 rb	2,96 jt	4,61 jt
Biaya depresiasi dan amortisasi	-	-	-	-
EBITDA	-28,35 jt	17,82 jt	63,26 jt	28,25 jt
Keuntungan atau kerugian dari penjualan aset	-	-	-	-

Konten AI mungkin berisi kesalahan. Pelajari lebih lanjut

BantuanKirim masukanPrivasi Persyaratan Pernyataan penyangkalan

Finance

Riset